Can I Take Lion's Mane with Vyleesi (Bremelanotide)? A Women's Health Guide

What Is Vyleesi and Why Do Women Use It?

Bremelanotide, sold as Vyleesi, is a subcutaneous injectable approved by the FDA in August 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD means persistently low sexual desire that causes personal distress. It is not a lifestyle drug. The FDA label restricts its use to premenopausal women, which means it is not approved or studied in postmenopausal or perimenopausal populations.

How bremelanotide works

Vyleesi activates melanocortin receptors, specifically MC3R and MC4R, in the central nervous system. This receptor activation modulates dopaminergic and serotonergic pathways involved in sexual motivation. You inject it into your abdomen or thigh at least 45 minutes before anticipated sexual activity, no more than once every 24 hours, and no more than once per day as needed. Phase 3 trials (RECONNECT) showed bremelanotide produced a statistically significant increase in satisfying sexual events compared with placebo, though effect sizes were modest.

Who is diagnosed with HSDD

Estimates suggest HSDD affects roughly 10% of premenopausal women in the United States, making it the most common female sexual dysfunction diagnosis. Many women search for both prescription options and complementary approaches, which is exactly where lion's mane enters the conversation.

Known side effects you should already know about

The most common adverse effects of bremelanotide are nausea (affecting roughly 40% of users in clinical trials), flushing, and a transient rise followed by a drop in blood pressure. The prescribing information notes a mean maximum decrease in systolic blood pressure of approximately 6 mmHg and in diastolic blood pressure of approximately 4 mmHg, occurring within 12 hours of injection. This blood-pressure effect is relevant when you add any supplement that may also influence vascular tone.

What Is Lion's Mane and Why Are Women Taking It?

Lion's mane (Hericium erinaceus) is an edible medicinal mushroom widely marketed for cognitive support, mood, and nerve health. Women take it for brain fog, anxiety, perimenopausal cognitive symptoms, and, increasingly, libido. Supplement sales data suggest it is one of the fastest-growing functional mushroom categories, though that commercial context should not be confused with clinical evidence.

The active compounds and their mechanisms

Lion's mane contains two families of bioactive compounds: hericenones (found in the fruiting body) and erinacines (found in the mycelium). Both families stimulate the production of nerve growth factor (NGF), a protein that supports neuron survival and differentiation. Animal studies show erinacines cross the blood-brain barrier. Whether NGF stimulation in humans translates to measurable cognitive or mood benefits at typical supplement doses (500 mg to 3,000 mg daily) remains contested.

What the human trial data actually shows

A small double-blind randomized controlled trial published in Phytotherapy Research (Mori et al., 2009) enrolled 30 adults (age 50 to 80) with mild cognitive impairment. Participants taking 3 g/day of Hericium erinaceus powder for 16 weeks scored significantly higher on a cognitive function scale than placebo. Scores declined after discontinuation. The study enrolled both sexes; no sex-disaggregated results were published. That is a meaningful evidence gap for women trying to extrapolate benefits. A 2023 pilot RCT (Ratto et al.) found lion's mane improved mild depressive symptoms and sleep quality in a mixed-sex sample of 41 adults over 4 weeks at 1.8 g/day.

Lion's mane and bleeding risk: what you need to know

Multiple in vitro and animal studies indicate that Hericium erinaceus extracts may inhibit platelet aggregation. A 2010 study in Journal of Agricultural and Food Chemistry (Kim et al.) demonstrated dose-dependent antiplatelet activity in vitro. This does not mean every woman taking lion's mane capsules will bleed more. It does mean that combining lion's mane with any drug that affects vascular tone, or before procedures, warrants clinical attention.

The Core Question: Does Lion's Mane Interact with Vyleesi?

No published pharmacokinetic or pharmacodynamic interaction study exists between bremelanotide and Hericium erinaceus. That absence of data is not reassurance. It is a data gap. Here is what can be reasoned from first principles.

Pharmacokinetic interaction: is it likely?

Bremelanotide is metabolized primarily via hydrolysis of the amide bonds, not via cytochrome P450 enzymes. This is an important distinction. Many drug-supplement interactions occur because both substances compete for the same CYP450 enzyme (CYP3A4, CYP2D6, etc.). Because bremelanotide bypasses this metabolic pathway, lion's mane, which has not been shown to meaningfully inhibit or induce any major CYP isoform, is unlikely to alter blood levels of bremelanotide.

The half-life of bremelanotide is approximately 2.7 hours. It clears your system within 12 to 24 hours after a single dose. Lion's mane is taken daily as a supplement, so there is always overlap between the two.

Verdict on pharmacokinetic interaction: low probability based on current evidence.

Pharmacodynamic interaction: where the real concern lives

This is the more clinically meaningful question. Two pharmacodynamic signals deserve attention.

Blood pressure. Bremelanotide reliably causes a transient blood-pressure decrease after injection. If you are also taking lion's mane, which in animal models has shown mild vasodilatory properties via nitric oxide pathways (reported in a 2014 study in Evidence-Based Complementary and Alternative Medicine), there is a theoretical additive hypotensive effect. The magnitude of this effect in humans is unknown. For most healthy premenopausal women with normal blood pressure, a combined small drop is unlikely to cause symptoms. If you already have low blood pressure, take antihypertensives, or are prone to orthostatic symptoms, this combination deserves more caution.

Platelet aggregation and bleeding. Bremelanotide itself does not appear to have antiplatelet effects. But if lion's mane mildly inhibits platelets and you take it daily, then add bremelanotide acutely, there is no known synergistic bleeding mechanism between the two specific pathways involved. The risk is not zero, but it is theoretical and probably small for a healthy woman not on anticoagulants.

A practical framework for evaluating this combination:

| Interaction type | Likelihood | Clinical significance | Action | |---|---|---|---| | CYP450 pharmacokinetic | Very low | Minimal | No dose adjustment needed | | Blood pressure (additive) | Low to moderate | Mild for most; watch if BP runs low | Monitor; sit or lie down after injection | | Antiplatelet (additive) | Low | Mild unless on other blood thinners | Disclose to prescriber | | NGF pathway and melanocortin | Unknown | No known overlap | No action required | | Serotonin system overlap | Theoretical | Uncertain | Disclose to prescriber |

Pregnancy, Lactation, and Contraception: Critical Warnings

Vyleesi (bremelanotide) is contraindicated in pregnancy. This is not a precautionary statement buried in small print. It is a firm contraindication.

The FDA prescribing label states that bremelanotide caused fetal harm in animal reproduction studies, including reduced pup survival and fetal weight at doses below the recommended human dose. Human data are insufficient to establish safety. If you become pregnant while using Vyleesi, stop immediately and contact your prescriber.

Contraception requirement

Because Vyleesi is approved only for premenopausal women (many of whom are of childbearing potential), the FDA label recommends that women who could become pregnant use effective contraception during treatment. The label advises discontinuing Vyleesi at least one menstrual cycle before attempting conception, to allow complete clearance and reduce any risk of inadvertent early-pregnancy exposure.

Breastfeeding and lactation

Animal data show bremelanotide is present in rat milk. There are no human lactation studies. The prescribing information advises against use during breastfeeding because of the potential for serious adverse effects in the infant. If you are postpartum and breastfeeding and experiencing low desire (which is extremely common due to prolactin suppression of estrogen), discuss alternative approaches with your OB-GYN or reproductive endocrinologist before reaching for Vyleesi.

Lion's mane in pregnancy and lactation

No controlled safety data exist for lion's mane in pregnant or breastfeeding women. Given the absence of safety data and its in vitro platelet effects, most clinicians recommend avoiding lion's mane during pregnancy and lactation. This is a precautionary position, not a documented risk.

Life-Stage Considerations Across Reproductive Years

Reproductive years (menstruating, not trying to conceive)

This is the FDA-approved window for Vyleesi. HSDD in this group may be driven by hormonal contraception (oral contraceptives can lower free testosterone and androgen-receptor sensitivity), stress, relationship factors, or thyroid dysfunction. Before starting Vyleesi, your prescriber should rule out underlying causes.

If you take lion's mane for cycle-related brain fog or mood, timing matters. Bremelanotide is used on an as-needed basis, not daily. Taking your lion's mane dose at least 2 hours before or after your Vyleesi injection is a reasonable spacing strategy until more data exist.

Trying to conceive

Stop Vyleesi. The contraindication is clear. Low desire while trying to conceive is genuinely common and often linked to the performance pressure of timed intercourse, cycle-tracking anxiety, or subclinical thyroid issues. A reproductive endocrinologist or fertility-aware OB-GYN can help.

Lion's mane is also not studied in women actively trying to conceive. Given the antiplatelet signal and lack of safety data, pausing it during this window is prudent.

Perimenopause

Vyleesi is not FDA-approved for perimenopausal or postmenopausal women. The RECONNECT trials enrolled exclusively premenopausal participants. If you are in perimenopause and experiencing low desire, the evidence base points more strongly toward testosterone therapy (studied in postmenopausal women in trials like the APHRODITE study) or treating underlying hormonal fluctuation with appropriate menopausal hormone therapy. The Menopause Society (NAMS) 2022 hormone therapy position statement does not endorse off-label bremelanotide for perimenopausal HSDD.

Lion's mane has been studied for cognitive symptoms in older adults, and perimenopausal brain fog is a real clinical complaint. But that is a separate conversation from HSDD treatment, and you should not assume a supplement marketed for brain fog will address desire.

Postmenopause

Vyleesi should not be used. Period. If a prescriber offers it off-label for postmenopausal HSDD, ask them to walk you through the evidence (or lack thereof) and discuss on-label alternatives.

Female-Relevant Conditions That Change the Risk Picture

PCOS

Women with polycystic ovary syndrome may already have dysregulated androgen levels, which can affect sexual desire in complex ways. Some women with PCOS experience higher-than-average desire early in their condition and lower desire later, particularly if they are on hormonal contraception to manage symptoms. If you have PCOS and are considering Vyleesi, your prescriber should evaluate your androgen status and rule out testosterone deficiency or excess as a contributing factor.

Lion's mane has no documented interaction with androgen pathways in women, though this is genuinely understudied.

Endometriosis and hormonal medications

Women with endometriosis often take continuous progestin or GnRH agonists, both of which can suppress desire. Adding Vyleesi in this context has not been studied. Combining lion's mane with GnRH agonists is also undocumented. Disclose all supplements to the prescriber managing your endometriosis.

Thyroid conditions

Hypothyroidism is strongly associated with low libido. Subclinical hypothyroidism affects up to 10% of women, and it is frequently underdiagnosed. Before attributing low desire to HSDD, a TSH level is a basic diagnostic step. Lion's mane has been marketed as having vague "thyroid-supportive" properties; the evidence for this in humans is essentially nonexistent.

Female pattern hair loss

This is a secondary consideration, but worth naming. Bremelanotide's mechanism of action involves melanocortin receptors, and MC1R activation affects pigmentation. Some women using Vyleesi report transient facial flushing and, in a small number of cases, focal hyperpigmentation of the face, breasts, or gums. This is documented in the prescribing information. Lion's mane has no known pigmentation effects.

What to Actually Do If You Are Already Taking Both

If you are currently taking lion's mane daily and have been prescribed Vyleesi, here is a step-by-step approach.

Step one: disclose. Tell your prescriber or pharmacist you are taking lion's mane, the dose, and the brand (fruiting body vs mycelium-based products differ in their erinacine content). Many prescribers do not ask about supplements proactively.

Step two: check your blood pressure before use. Bremelanotide causes a transient blood-pressure dip. If your baseline blood pressure is already on the lower side (systolic <100 mmHg), monitor for lightheadedness after injection.

Step three: time the doses. Take your lion's mane supplement at least 2 hours before your Vyleesi injection, or take it later in the day after the drug has begun to clear. Bremelanotide reaches peak plasma concentration within approximately 1 hour of injection and has a half-life of roughly 2.7 hours.

Step four: watch for bleeding signals. If you notice unusual bruising, heavier menstrual bleeding, or prolonged bleeding from minor cuts, report it. This is unlikely to be caused by lion's mane at standard doses, but it is worth monitoring if you are on any additional supplement or medication with antiplatelet properties (fish oil, ginkgo, aspirin).

Step five: reassess every treatment cycle. HSDD is not necessarily permanent. Check in with your prescriber every 3 months on whether Vyleesi is still the right tool.

The Evidence Gap: What We Do Not Know and Why It Matters

Women have historically been underrepresented in both clinical pharmacology trials and supplement safety research. The RECONNECT bremelanotide trials did enroll only women, which is appropriate given the indication, but they did not assess supplement co-administration. Lion's mane research, where it exists, is predominantly from Asia, in older mixed-sex populations, using preparations that may not match what is sold in US supplements.

A 2022 systematic review of medicinal mushroom clinical trials found that fewer than 20% of trials reported sex-disaggregated outcomes. This means virtually nothing in the lion's mane literature was analyzed for differential effects in women by hormonal status, cycle phase, or menopausal stage.

The practical implication: no one can tell you definitively that this combination is safe, because the studies have not been done. That uncertainty belongs in this article, not buried under reassuring language. Your prescriber may say the risk is low, and they may be right, but they are extrapolating from incomplete data.

Who This Combination Is Likely Right For (and Not Right For)

Likely a reasonable approach (with disclosure)

You are a premenopausal woman diagnosed with HSDD by a clinician who has ruled out hormonal causes. You have normal blood pressure. You are not on anticoagulants or other antiplatelet supplements. You use effective contraception. You have disclosed lion's mane to your prescriber and they have no specific objection.

More caution warranted

Your blood pressure runs low, you have a clotting disorder, you take aspirin or fish oil at high doses, you are postpartum and breastfeeding, or you are actively trying to conceive.

Should not use Vyleesi at all

You are pregnant. You are postmenopausal (no approved indication). You have uncontrolled cardiovascular disease (bremelanotide is not recommended in women with high cardiovascular risk per the FDA label).